CureVac and Novartis sign initial agreement on manufacturing of COVID-19 vaccine candidate
BOSTON – CureVac N.V. and Novartis AG announced Thursday that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway. Following final agreement, Novartis plans to manufacture the mRNA and bulk drug product of the CVnCoV
